No connection

Search Results

AMN vs KURA

AMN
AMN Healthcare Services, Inc.
BEARISH
Price
$20.49
Market Cap
$787.1M
Sector
Healthcare
AI Confidence
78%
KURA
Kura Oncology, Inc.
BEARISH
Price
$8.67
Market Cap
$765.8M
Sector
Healthcare
AI Confidence
85%

Valuation

P/E Ratio
AMN
--
KURA
--
Forward P/E
AMN
30.31
KURA
-3.55
P/B Ratio
AMN
1.22
KURA
4.37
P/S Ratio
AMN
0.29
KURA
11.35
EV/EBITDA
AMN
7.87
KURA
-0.39

Profitability

Gross Margin
AMN
29.37%
KURA
-272.14%
Operating Margin
AMN
1.33%
KURA
-497.62%
Profit Margin
AMN
-10.14%
KURA
0.0%
ROE
AMN
-35.9%
KURA
-94.82%
ROA
AMN
1.17%
KURA
-25.33%

Growth

Revenue Growth
AMN
-7.7%
KURA
-67.8%
Earnings Growth
AMN
321.3%
KURA
--

Financial Health

Debt/Equity
AMN
1.37
KURA
0.12
Current Ratio
AMN
1.05
KURA
6.06
Quick Ratio
AMN
0.94
KURA
5.81

Dividends

Dividend Yield
AMN
--
KURA
--
Payout Ratio
AMN
0.0%
KURA
0.0%

AI Verdict

AMN BEARISH

The company exhibits severe financial distress with a Piotroski F-Score of just 2/9, indicating weak fundamental health. Despite recent earnings surprises and short-term EPS growth, the business is unprofitable (negative profit margin and ROE), leveraged (Debt/Equity of 1.37), and has declining revenues. Valuation metrics like a high Forward P/E of 30.31 and low Price/Sales of 0.29 reflect inconsistent pricing signals, while the stock has lost over 70% of its value in the past five years. The absence of an Altman Z-Score due to insufficient data further raises concerns about financial stability.

Strengths
Consistently beats earnings estimates with an average surprise of over 90% in the last four quarters
Recent quarterly EPS growth (Q/Q) of +30.0% shows potential operational improvement
Operating margin remains positive at 1.33% despite overall net losses
Risks
Piotroski F-Score of 2/9 signals severe financial weakness and high risk of continued deterioration
Negative profit margin (-10.14%) and ROE (-35.90%) indicate persistent unprofitability and poor capital efficiency
Revenue declining YoY by 7.70%, reflecting shrinking top-line and potential market share loss
KURA BEARISH

KURA presents a contradictory profile with a stable Piotroski F-Score of 6/9 and exceptional liquidity (Current Ratio 6.06), yet suffers from severe fundamental decay. The company has experienced a catastrophic revenue decline of -67.80% YoY and has missed earnings estimates in four consecutive quarters with an average surprise of -50.91%. While the analyst target price of $31.82 suggests significant upside, this is decoupled from the current financial reality of negative gross margins (-272.14%) and bearish insider activity. The stock is currently a speculative play on pipeline success rather than a value or growth investment based on existing data.

Strengths
Strong liquidity position with a Current Ratio of 6.06
Very low leverage with a Debt/Equity ratio of 0.12
Stable Piotroski F-Score (6/9) indicating baseline operational stability
Risks
Severe revenue contraction (-67.80% YoY and Q/Q)
Consistent earnings misses (0/4 beats in the last year)
Deeply negative profitability (Operating Margin -497.62%)

Compare Another Pair

AMN vs KURA: Head-to-Head Comparison

This page compares AMN Healthcare Services, Inc. (AMN) and Kura Oncology, Inc. (KURA) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.

Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.

Home
Terminal
AI
Markets
Profile